Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01881243 · ClinicalTrials.gov registry record

Reoxygenation After Cardiac Arrest (REOX Study)

A clinical trial of Cardiac Arrest, sponsored by The Cooper Health System.

Completed
Registry status
280
Enrollment target
5
Study locations

NCT01881243 is a study of Cardiac Arrest that has completed, run by The Cooper Health System. The registered enrollment target is 280 participants, below the 1,471-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01881243, a study of Cardiac Arrest, has completed, sponsored by The Cooper Health System.

COMPLETED
Registry status
280 participants
Enrollment target
5
Study locations

Study Summary

The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. Our overarching hypothesis is that hyperoxia after ROSC is associated with increased oxidative stress and worsened neurological and cognitive outcomes.

Conditions Studied

Study Locations (5)

Indiana

  • Indiana University/ Methodist Hospital - Indianapolis

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Mississippi

  • University of Mississippi Medical Center - Jackson

New Jersey

  • Cooper University Hospital - Camden

Pennsylvania

  • Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2013-06
Est. Completion 2017-06

Sponsor

The Cooper Health System

39 total trials

What the Registry Record Tells You About NCT01881243

The ClinicalTrials.gov registry entry for NCT01881243 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,471-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (81% lower). The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiac Arrest appearing as the primary indexed condition, and to 0 interventions.

NCT01881243 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Indiana, Massachusetts, Mississippi.

Frequently Asked Questions

What is clinical trial NCT01881243 about?

NCT01881243 is a clinical study titled "Reoxygenation After Cardiac Arrest (REOX Study)". The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. Our overarching hypothesis is that hyperoxia after ROSC is associated with increased oxidative stress and worsened neurological and cognitive outcomes.

What is the current status of trial NCT01881243?

This trial is currently completed. The enrollment target is 280 participants. The study started on 2013-06. Estimated completion is 2017-06.

What conditions does trial NCT01881243 study?

This clinical trial studies the following conditions: Cardiac Arrest.

Who is sponsoring clinical trial NCT01881243?

This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01881243 being conducted?

This trial has 5 study locations across Indiana, Massachusetts, Mississippi, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiac Arrest

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.